ssPalmO-Phe|Ionizable Lipid for LNP

Cas No.:	2377474-67-2
Chemical Name:	ssPalmO-Phe
Synonyms:	Benzeneacetic acid, 4-[[(9Z )-1-oxo-9-octadecen-1-yl]oxy]-, 1,1′-[dithiobis(2,1-ethanediyl-1,4-piperidinediyl-2,1-ethanediyl)] ester (ACI);ssPalmOPhe， ssPalmO Phe
SMILES:	C(C(OCCC1CCN(CCSSCCN2CCC(CCOC(CC3=CC=C(OC(CCCCCCC/C=C\CCCCCCCC)=O)C=C3)=O)CC2)CC1)=O)C4=CC=C(OC(CCCCCCC/C= C\CCCCCCCC)=O)C=C4
Formula:	C₇₀H₁₁₂N₂O₈S₂
M.Wt:	1173.777
Purity:	ELSD-HPLC>95%
Sotrage:	1 year -20°C
Publication:	H. Tanaka, A. Watanabe, M. Konishi, Y. Nakai, H. Yoshioka, T. Ohkawara, H. Takeda, H. Harashima, H. Akita, Heliyon 2018, 4, e00959.

Cat. No.	Product name	Field of application
DC59002	ssPalmO-Phe	ssPalmO-Phe(SS-OP) is a self-degradable material for the delivery of oligonucleotides. ssPalmO-Phe is a self-degradable derivative of ssPalm that is self-degraded in the intraparticle space by a specific hydrolytic reaction. ssPalmO-Phe is beneficial for overcoming the plasma/endosomal membrane, LNP-ssPalmO-Phe can be used to deliver both nucleic acids.
DC57006	L319	L319 (LIPID 319) is a novel ionizable, biodegradable lipid for delivery of short interfering RNAs (siRNAs). L319-LPN displays rapid elimination with pKa of 6.38 and also shows well tolerated up to 10 mg/kg.
DC60782	Lipid A4B4-S3	A4B4-S3 is a novel biodegradable ionizable lipid that has been meticulously designed through modular platforms and optimized specifically for mRNA delivery. It serves as a critical component of lipid nanoparticles (LNPs) and enhances mRNA delivery efficiency by facilitating endosomal escape. The structural design of A4B4-S3 leverages the Passerini reaction, a highly efficient and modular chemical method that enables the rapid generation of diverse lipid libraries. The design focuses on optimizing the methylene units between lipid headgroups and linkages to strengthen hydrogen bonding interactions with mRNA ribophosphate complexes. This enhanced hydrogen bonding allows for more effective release of mRNA from endosomes, thereby boosting delivery efficiency. Concurrently, the structural optimization improves biodegradability, reducing potential long-term toxicity risks. In experimental studies, A4B4-S3 has demonstrated superior gene editing efficacy in mouse liver compared to SM-102, a clinically prevalent lipid used in Moderna's COVID-19 vaccine. It also shows potential for repeat-dose protein replacement therapies, suggesting enhanced stability and safety for long-term treatment regimens. Technologically, A4B4-S3 not only provides a more efficient LNP formulation but also deepens the understanding of the relationship between structure and delivery efficiency. This offers new directions for the development of future mRNA therapeutics. In summary, A4B4-S3 represents a next-generation delivery carrier achieved through rational design and high-throughput screening strategies. Its performance enhancements and biodegradable properties position it as a promising candidate for gene therapies and vaccine applications.